LA REINTRODUCTION DU GYPAETE BARBU (GYPAETUS BARBATTYS) DANS LES ALPES FRANCAISES

MAISONS-ALFORT-Ecole Vétérin (940462302) / SudocSudocFranceF

Rehydration behaviour and ageing of dairy powders assessed by calorimetric measurements

On the basis of dissolution enthalpy measurements, the aims of this study were i) to investigate the feasibility of lassifying the dissolvability of various dairy powders, and ii) to establish whether a change in rehydration behaviour that occurs with ageing could be predicted. No clear correlations could be established between the exothermic or endothermic nature of the calorimetric response and the rehydration ability of the powders studied. Dissolution enthalpy cannot thus be considered an absolute parameter that could be used to classify one dairy powder among others. On the contrary, it is experimentally shown that dissolution enthalpy is very sensitive both to the composition and the physical state of the powder. Consequently, dissolution enthalpy value can be considered as a marker representative of the manufacturing process and storage conditions. Evidence is made that following dissolution enthalpy over time could be a way to detect changes in powders due to ageing

Scénarios d’extrêmes hydrologiques

Le projet Explore2 a produit un ensemble de projections hydrologiques suivant plusieurs scénarios climatiques pour la France hexagonale. L’objet de ce rapport est de présenter les scénarios d’évolution des extrêmes hydrologiques, concernant les épisodes de pluies intenses, crues, sécheresses météorologiques, agronomiques, hydrologiques, hydrogéologiques et assecs des cours d’eau

introduction - travailler en agriculture

International audienc

Messages et enseignements du projet Explore2

Ce document résume les principales conclusions sur l'évolution de variables climatiques et hydrologiques (surface et souterrain) et des aléas hydroclimatiques, obtenues à l'issue du projet Explore2. Il s'achève par des messages et enseignements du projet Explore2 sur le volet scientifique et le volet accompagnement des acteurs

The Sociology of Work in France

International audienc

The ThomX ICS source

International audienceThomX is a new generation Compact Compton Source. It is currently commissioned by and at the IJCLab (Laboratoire de physique des 2 infinis - Irène Joliot-Curie (UMR9012)) at Orsay. The first beam is expected at the begining of 2021. The aim of ThomX is to demonstrate the characteristics of an intense and Compact (lab-size) X-ray source based on Compton Scattering. The performances are mostly driven by the laser optical system which is above the state of the art of stored laser power. Proof of principle of various X-ray techniques will be performed thanks to the versatile ThomX beamline. Firstly, this article presents the machine description. Secondly, the issues and limits of the laser system are discussed. Then, the ThomX beamline is described and the machine status conclude the ThomX presentation. Finally, the expected performances for the next years and the possible experiments that can be made with this new machine are detailed

First production of X-rays at the ThomX high-intensity Compton source

International audienceWith the increase in laser power and finesse of optical cavities over the last decade, laboratory-size Compton sources are very promising. These sources produce X-rays through interactions between relativistic electrons and laser photons and, in term of brightness, fall between large synchrotron facilities and classical laboratory X-ray sources. The ThomX source is the French project in this field. This article first presents a state of the art of high-intensity Compton sources, then the ThomX source is briefly described, and the first results are detailed, in particular the production of the first X-rays, the acquisition of the first spectrum and the first image of the beam. Finally, the next objectives are discussed

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

BackgroundSparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary endpoint) in patients with immunoglobulin A nephropathy in the phase 3 PROTECT trial's previously reported interim analysis. Here, we report kidney function and outcomes over 110 weeks from the double-blind final analysis.MethodsPROTECT, a double-blind, randomised, active-controlled, phase 3 study, was done across 134 clinical practice sites in 18 countries throughout the Americas, Asia, and Europe. Patients aged 18 years or older with biopsy-proven primary IgA nephropathy and proteinuria of at least 1·0 g per day despite maximised renin–angiotensin system inhibition for at least 12 weeks were randomly assigned (1:1) to receive sparsentan (target dose 400 mg oral sparsentan once daily) or irbesartan (target dose 300 mg oral irbesartan once daily) based on a permuted-block randomisation method. The primary endpoint was proteinuria change between treatment groups at 36 weeks. Secondary endpoints included rate of change (slope) of the estimated glomerular filtration rate (eGFR), changes in proteinuria, a composite of kidney failure (confirmed 40% eGFR reduction, end-stage kidney disease, or all-cause mortality), and safety and tolerability up to 110 weeks from randomisation. Secondary efficacy outcomes were assessed in the full analysis set and safety was assessed in the safety set, both of which were defined as all patients who were randomly assigned and received at least one dose of randomly assigned study drug. This trial is registered with ClinicalTrials.gov, NCT03762850.FindingsBetween Dec 20, 2018, and May 26, 2021, 203 patients were randomly assigned to the sparsentan group and 203 to the irbesartan group. One patient from each group did not receive the study drug and was excluded from the efficacy and safety analyses (282 [70%] of 404 included patients were male and 272 [67%] were White) . Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6–110) was −2·7 mL/min per 1·73 m2 per year versus −3·8 mL/min per 1·73 m2 per year (difference 1·1 mL/min per 1·73 m2 per year, 95% CI 0·1 to 2·1; p=0·037); total 2-year slope (day 1–week 110) was −2·9 mL/min per 1·73 m2 per year versus −3·9 mL/min per 1·73 m2 per year (difference 1·0 mL/min per 1·73 m2 per year, 95% CI −0·03 to 1·94; p=0·058). The significant reduction in proteinuria at 36 weeks with sparsentan was maintained throughout the study period; at 110 weeks, proteinuria, as determined by the change from baseline in urine protein-to-creatinine ratio, was 40% lower in the sparsentan group than in the irbesartan group (−42·8%, 95% CI −49·8 to −35·0, with sparsentan versus −4·4%, −15·8 to 8·7, with irbesartan; geometric least-squares mean ratio 0·60, 95% CI 0·50 to 0·72). The composite kidney failure endpoint was reached by 18 (9%) of 202 patients in the sparsentan group versus 26 (13%) of 202 patients in the irbesartan group (relative risk 0·7, 95% CI 0·4 to 1·2). Treatment-emergent adverse events were well balanced between sparsentan and irbesartan, with no new safety signals.InterpretationOver 110 weeks, treatment with sparsentan versus maximally titrated irbesartan in patients with IgA nephropathy resulted in significant reductions in proteinuria and preservation of kidney function